Dose Escalation Study of Paclitaxel in Combination with Fixed-Dose Irinotecan in Patients with Advanced Non-Small Cell Lung Cancer (JCOG 9807)

Publisher： Karger

E-ISSN： 1423-0232|66|2|94-100

ISSN： 0030-2414

Source： Oncology, Vol.66, Iss.2, 2004-05, pp. : 94-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Escalation Study of Amrubicin in Combination with Fixed-Dose Irinotecan in Patients with Extensive Small-Cell Lung Cancer

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 7-11

Karger

Access to resources Recommend Favorite

Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose Escalation and Pharmacokinetic Study of Carboplatin plus Pemetrexed for Elderly Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group Trial 1002

By  

Oncology, Vol. 88, Iss. 4, 2014-12 ,pp. : 201-207

Karger

Access to resources Recommend Favorite

Phase II Study of Irinotecan and Ifosfamide in Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 306-311

Karger

Access to resources Recommend Favorite